[{"id":"b6ca3d93-c186-4751-9a4a-5de77d5b1a3b","acronym":"MOUNTAINEER-03","url":"https://clinicaltrials.gov/study/NCT05253651","created_at":"2022-02-24T14:52:50.182Z","updated_at":"2025-02-25T13:36:05.619Z","phase":"Phase 3","brief_title":"A Study of Tucatinib With Trastuzumab and mFOLFOX6 Versus Standard of Care Treatment in First-line HER2+ Metastatic Colorectal Cancer","source_id_and_acronym":"NCT05253651 - MOUNTAINEER-03","lead_sponsor":"Seagen Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" RAS wild-type","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e RAS wild-type"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Avastin (bevacizumab) • Herceptin (trastuzumab) • Erbitux (cetuximab) • 5-fluorouracil • oxaliplatin • Tukysa (tucatinib) • leucovorin calcium • levoleucovorin calcium"],"overall_status":"Recruiting","enrollment":" Enrollment 400","initiation":"Initiation: 10/24/2022","start_date":" 10/24/2022","primary_txt":" Primary completion: 04/03/2026","primary_completion_date":" 04/03/2026","study_txt":" Completion: 07/27/2029","study_completion_date":" 07/27/2029","last_update_posted":"2025-02-21"},{"id":"16a15023-befe-4ca0-9aaa-23efe0cc2225","acronym":"MK-7119-001","url":"https://clinicaltrials.gov/study/NCT04721977","created_at":"2021-01-25T15:53:18.932Z","updated_at":"2025-02-25T13:49:04.272Z","phase":"Phase 2","brief_title":"A Study of Tucatinib (MK-7119) in Combination With Trastuzumab and Capecitabine in Participants With Previously Treated Locally Advanced Unresectable or Metastatic Human Epidermal Growth Factor Receptor 2 Positive (HER2+) Breast Carcinoma (MK-7119-001)","source_id_and_acronym":"NCT04721977 - MK-7119-001","lead_sponsor":"Pfizer","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • capecitabine • Tukysa (tucatinib) • Herceptin Hylecta (trastuzumab/hyaluronidase-oysk)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 04/08/2021","start_date":" 04/08/2021","primary_txt":" Primary completion: 07/17/2023","primary_completion_date":" 07/17/2023","study_txt":" Completion: 11/25/2025","study_completion_date":" 11/25/2025","last_update_posted":"2025-02-20"},{"id":"e6f0f0cd-c6bf-46b7-8b76-a1dbcf03e0df","acronym":"HER2CLIMB-04","url":"https://clinicaltrials.gov/study/NCT04539938","created_at":"2021-07-05T17:32:09.274Z","updated_at":"2025-02-25T14:02:02.863Z","phase":"Phase 2","brief_title":"A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer","source_id_and_acronym":"NCT04539938 - HER2CLIMB-04","lead_sponsor":"Seagen, a wholly owned subsidiary of Pfizer","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enhertu (fam-trastuzumab deruxtecan-nxki) • Tukysa (tucatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 70","initiation":"Initiation: 12/01/2020","start_date":" 12/01/2020","primary_txt":" Primary completion: 07/15/2024","primary_completion_date":" 07/15/2024","study_txt":" Completion: 07/01/2025","study_completion_date":" 07/01/2025","last_update_posted":"2025-02-19"},{"id":"e2a7e1c5-e873-49a1-9d76-b61c5d386ab0","acronym":"DESTINY-Breast07","url":"https://clinicaltrials.gov/study/NCT04538742","created_at":"2021-01-18T21:43:10.527Z","updated_at":"2025-02-25T13:53:25.796Z","phase":"Phase 1/2","brief_title":"A Phase 1b/2 Study of T-DXd Combinations in HER2-positive Metastatic Breast Cancer","source_id_and_acronym":"NCT04538742 - DESTINY-Breast07","lead_sponsor":"AstraZeneca","biomarkers":" HER-2 • PGR","pipe":" | ","alterations":" HER-2 positive • HR positive","tags":["HER-2 • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Imfinzi (durvalumab) • paclitaxel • Perjeta (pertuzumab) • Enhertu (fam-trastuzumab deruxtecan-nxki) • Tukysa (tucatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 245","initiation":"Initiation: 12/28/2020","start_date":" 12/28/2020","primary_txt":" Primary completion: 01/31/2025","primary_completion_date":" 01/31/2025","study_txt":" Completion: 01/31/2030","study_completion_date":" 01/31/2030","last_update_posted":"2025-02-14"},{"id":"f231b1ba-c963-4fcd-a957-1503f6a6f741","acronym":"SGNTUC 024","url":"https://clinicaltrials.gov/study/NCT04430738","created_at":"2021-01-18T21:20:17.873Z","updated_at":"2025-02-25T16:37:54.749Z","phase":"Phase 1/2","brief_title":"Tucatinib Plus Trastuzumab and Oxaliplatin-based Chemotherapy or Pembrolizumab-containing Combinations for HER2+ Gastrointestinal Cancers","source_id_and_acronym":"NCT04430738 - SGNTUC 024","lead_sponsor":"Seagen Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Herceptin (trastuzumab) • 5-fluorouracil • capecitabine • oxaliplatin • Tukysa (tucatinib) • leucovorin calcium"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 41","initiation":"Initiation: 09/15/2020","start_date":" 09/15/2020","primary_txt":" Primary completion: 07/31/2024","primary_completion_date":" 07/31/2024","study_txt":" Completion: 10/31/2025","study_completion_date":" 10/31/2025","last_update_posted":"2025-02-06"},{"id":"47a36b91-3872-4bf3-8c5d-910cdf540cd0","acronym":"TUGETHER","url":"https://clinicaltrials.gov/study/NCT04789096","created_at":"2021-03-09T15:52:25.212Z","updated_at":"2025-02-25T16:45:21.897Z","phase":"Phase 2","brief_title":"Tucatinib Together with Pembrolizumab and Trastuzumab","source_id_and_acronym":"NCT04789096 - TUGETHER","lead_sponsor":"Breast Cancer Trials, Australia and New Zealand","biomarkers":" HER-2 • PD-L1","pipe":" | ","alterations":" PD-L1 expression • HER-2 positive • HER-2 amplification • HER-2 expression • PD-L1 negative","tags":["HER-2 • PD-L1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • HER-2 positive • HER-2 amplification • HER-2 expression • PD-L1 negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Herceptin (trastuzumab) • capecitabine • Tukysa (tucatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 57","initiation":"Initiation: 03/07/2023","start_date":" 03/07/2023","primary_txt":" Primary completion: 09/30/2025","primary_completion_date":" 09/30/2025","study_txt":" Completion: 09/01/2026","study_completion_date":" 09/01/2026","last_update_posted":"2025-02-05"},{"id":"b7048987-4b11-4fd9-aa58-5084a07ea2c4","acronym":"CLIMB-LMD","url":"https://clinicaltrials.gov/study/NCT06016387","created_at":"2023-08-29T16:10:21.403Z","updated_at":"2025-02-25T17:39:13.683Z","phase":"Phase 2","brief_title":"Tucatinib With Brain and/or Spinal XRT in Patients With HER2+ Metastatic Breast Cancer and LMD","source_id_and_acronym":"NCT06016387 - CLIMB-LMD","lead_sponsor":"Sunnybrook Health Sciences Centre","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • capecitabine • Tukysa (tucatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 30","initiation":"Initiation: 11/25/2023","start_date":" 11/25/2023","primary_txt":" Primary completion: 10/05/2025","primary_completion_date":" 10/05/2025","study_txt":" Completion: 10/05/2028","study_completion_date":" 10/05/2028","last_update_posted":"2025-01-29"},{"id":"d8a6d977-6f13-416a-b8b4-9b7236d1ef6b","acronym":"TAPUR","url":"https://clinicaltrials.gov/study/NCT02693535","created_at":"2021-01-17T17:24:20.327Z","updated_at":"2025-02-25T14:00:57.498Z","phase":"Phase 2","brief_title":"TAPUR: Testing the Use of Food and Drug Administration (FDA) Approved Drugs That Target a Specific Abnormality in a Tumor Gene in People With Advanced Stage Cancer","source_id_and_acronym":"NCT02693535 - TAPUR","lead_sponsor":"American Society of Clinical Oncology","biomarkers":" BRAF","pipe":" | ","alterations":" ER positive • HER-2 negative • PGR positive","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • HER-2 negative • PGR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Xalkori (crizotinib) • Tecentriq (atezolizumab) • Gilotrif (afatinib) • Yervoy (ipilimumab) • Ibrance (palbociclib) • Zelboraf (vemurafenib) • Imfinzi (durvalumab) • Vitrakvi (larotrectinib) • Rozlytrek (entrectinib) • sunitinib • tamoxifen • Perjeta (pertuzumab) • Cotellic (cobimetinib) • Bavencio (avelumab) • Talzenna (talazoparib) • Verzenio (abemaciclib) • albumin-bound paclitaxel • cyclophosphamide • Stivarga (regorafenib) • fulvestrant • Lytgobi (futibatinib) • Tukysa (tucatinib) • temsirolimus • letrozole • axitinib • epirubicin • anastrozole • exemestane • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf) • leuprolide acetate for depot suspension"],"overall_status":"Recruiting","enrollment":" Enrollment 3791","initiation":"Initiation: 03/14/2016","start_date":" 03/14/2016","primary_txt":" Primary completion: 06/30/2026","primary_completion_date":" 06/30/2026","study_txt":" Completion: 06/30/2027","study_completion_date":" 06/30/2027","last_update_posted":"2025-01-29"},{"id":"3321b9eb-4041-44b7-9b45-28169a5b88a3","acronym":"BRIDGET","url":"https://clinicaltrials.gov/study/NCT05323955","created_at":"2022-04-12T13:52:41.307Z","updated_at":"2025-02-25T12:28:44.690Z","phase":"Phase 2","brief_title":"Secondary BRain Metastases Prevention After Isolated Intracranial Progression on Trastuzumab/Pertuzumab or T-DM1 in Patients with ADvanced Human Epidermal Growth Factor Receptor 2+ BrEast Cancer with the Addition of Tucatinib","source_id_and_acronym":"NCT05323955 - BRIDGET","lead_sponsor":"Carey Anders, M.D.","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • Tukysa (tucatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 48","initiation":"Initiation: 03/23/2023","start_date":" 03/23/2023","primary_txt":" Primary completion: 10/01/2026","primary_completion_date":" 10/01/2026","study_txt":" Completion: 10/01/2027","study_completion_date":" 10/01/2027","last_update_posted":"2024-12-11"},{"id":"a13755c9-9b6b-401a-b3fb-aa0e5d28f3a0","acronym":"HER2CLIMB-05","url":"https://clinicaltrials.gov/study/NCT05132582","created_at":"2021-11-24T18:55:36.265Z","updated_at":"2025-02-25T13:54:06.899Z","phase":"Phase 3","brief_title":"A Study of Tucatinib or Placebo With Trastuzumab and Pertuzumab for Metastatic HER2+ Breast Cancer","source_id_and_acronym":"NCT05132582 - HER2CLIMB-05","lead_sponsor":"Seagen Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HR positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HR positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Perjeta (pertuzumab) • Tukysa (tucatinib) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 654","initiation":"Initiation: 03/07/2022","start_date":" 03/07/2022","primary_txt":" Primary completion: 05/31/2025","primary_completion_date":" 05/31/2025","study_txt":" Completion: 10/31/2027","study_completion_date":" 10/31/2027","last_update_posted":"2024-11-13"},{"id":"613dfa54-e318-471f-a8ed-a12b2572968b","acronym":"CAPTUR","url":"https://clinicaltrials.gov/study/NCT03297606","created_at":"2021-01-18T16:17:30.914Z","updated_at":"2025-02-25T13:52:23.697Z","phase":"Phase 2","brief_title":"Canadian Profiling and Targeted Agent Utilization Trial (CAPTUR)","source_id_and_acronym":"NCT03297606 - CAPTUR","lead_sponsor":"Canadian Cancer Trials Group","biomarkers":" BRAF","pipe":"","alterations":" ","tags":["BRAF"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Opdivo (nivolumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • Xalkori (crizotinib) • erlotinib • Yervoy (ipilimumab) • Ibrance (palbociclib) • dasatinib • Zelboraf (vemurafenib) • sunitinib • Perjeta (pertuzumab) • Cotellic (cobimetinib) • bosutinib • Tukysa (tucatinib) • temsirolimus • axitinib • Erivedge (vismodegib)"],"overall_status":"Recruiting","enrollment":" Enrollment 720","initiation":"Initiation: 03/23/2018","start_date":" 03/23/2018","primary_txt":" Primary completion: 01/31/2026","primary_completion_date":" 01/31/2026","study_txt":" Completion: 01/31/2027","study_completion_date":" 01/31/2027","last_update_posted":"2024-11-12"},{"id":"8cf55ab0-20f6-44cb-8bda-ecaebf4b0cba","acronym":"I-SPY 2","url":"https://clinicaltrials.gov/study/NCT01042379","created_at":"2021-01-17T17:27:23.313Z","updated_at":"2025-02-25T12:25:36.876Z","phase":"Phase 2","brief_title":"I-SPY TRIAL: Neoadjuvant and Personalized Adaptive Novel Agents to Treat Breast Cancer","source_id_and_acronym":"NCT01042379 - I-SPY 2","lead_sponsor":"QuantumLeap Healthcare Collaborative","biomarkers":" HER-2 • ER","pipe":" | ","alterations":" ER positive • ER negative","tags":["HER-2 • ER"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ER positive • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Herceptin (trastuzumab) • Lynparza (olaparib) • carboplatin • Imfinzi (durvalumab) • paclitaxel • Nerlynx (neratinib) • Perjeta (pertuzumab) • Kadcyla (ado-trastuzumab emtansine) • doxorubicin hydrochloride • Talzenna (talazoparib) • Verzenio (abemaciclib) • Zejula (niraparib) • cyclophosphamide • irinotecan • Jemperli (dostarlimab-gxly) • Tukysa (tucatinib) • letrozole • veliparib (ABT-888) • Libtayo (cemiplimab-rwlc) • MK-2206 • Datroway (datopotamab deruxtecan-dlnk) • Ziihera (zanidatamab-hrii) • ganitumab (AMG 479) • amcenestrant (SAR439859) • anvatabart opadotin (JNJ-0683) • metformin • Jivadco (trastuzumab duocarmazine) • Turalio (pexidartinib) • ganetespib (ADX-1612) • vepdegestrant (ARV-471) • Cosela (trilaciclib) • Fablyn (lasofoxifene) • DAN-222 • fianlimab (REGN3767) • Oraxol (oral paclitaxel/encequidar) • ladiratuzumab vedotin (SGN-LIV1A) • nelitolimod (SD-101) • patritumab (U3-1287) • rilvegostomig (AZD2936) • trebananib (AMG 386) • Kevzara (sarilumab) • Voyager-V1"],"overall_status":"Recruiting","enrollment":" Enrollment 5000","initiation":"Initiation: 03/01/2010","start_date":" 03/01/2010","primary_txt":" Primary completion: 12/01/2030","primary_completion_date":" 12/01/2030","study_txt":" Completion: 12/01/2031","study_completion_date":" 12/01/2031","last_update_posted":"2024-10-22"},{"id":"c07d9f42-9545-4b26-adaf-48377c037340","acronym":"InTTercePT","url":"https://clinicaltrials.gov/study/NCT05041842","created_at":"2021-09-13T14:55:47.756Z","updated_at":"2025-02-25T12:28:21.737Z","phase":"Phase 2","brief_title":"Treatment With Tucatinib in Patients With an Isolated Brain Progression of a Metastatic Breast Cancer","source_id_and_acronym":"NCT05041842 - InTTercePT","lead_sponsor":"UNICANCER","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Perjeta (pertuzumab) • fulvestrant • Tukysa (tucatinib) • Phesgo (pertuzumab/trastuzumab/hyaluronidase-zzxf)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 53","initiation":"Initiation: 12/17/2021","start_date":" 12/17/2021","primary_txt":" Primary completion: 04/30/2025","primary_completion_date":" 04/30/2025","study_txt":" Completion: 04/30/2026","study_completion_date":" 04/30/2026","last_update_posted":"2024-10-17"},{"id":"00bd59ae-be75-47ee-9ac3-1f4257c77d9d","acronym":"HER2CLIMB-02","url":"https://clinicaltrials.gov/study/NCT03975647","created_at":"2021-01-18T19:33:15.474Z","updated_at":"2024-07-02T16:34:27.156Z","phase":"Phase 3","brief_title":"A Study of Tucatinib vs. Placebo in Combination With Ado-trastuzumab Emtansine (T-DM1) for Patients With Advanced or Metastatic HER2+ Breast Cancer","source_id_and_acronym":"NCT03975647 - HER2CLIMB-02","lead_sponsor":"Seagen Inc.","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Kadcyla (ado-trastuzumab emtansine) • Tukysa (tucatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 565","initiation":"Initiation: 10/02/2019","start_date":" 10/02/2019","primary_txt":" Primary completion: 06/29/2023","primary_completion_date":" 06/29/2023","study_txt":" Completion: 10/31/2027","study_completion_date":" 10/31/2027","last_update_posted":"2024-06-11"},{"id":"c1d55f5b-2f1e-433d-be41-743b5f5540d8","acronym":"ACE-Breast-3","url":"https://clinicaltrials.gov/study/NCT04829604","created_at":"2021-04-02T11:53:47.301Z","updated_at":"2024-07-02T16:34:27.450Z","phase":"Phase 2","brief_title":"ARX788 in HER2-positive, Metastatic Breast Cancer Subjects (ACE-Breast-03)","source_id_and_acronym":"NCT04829604 - ACE-Breast-3","lead_sponsor":"Ambrx, Inc.","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 positive","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Enhertu (fam-trastuzumab deruxtecan-nxki) • Tukysa (tucatinib) • anvatabart opadotin (JNJ-0683)"],"overall_status":"Recruiting","enrollment":" Enrollment 71","initiation":"Initiation: 10/26/2021","start_date":" 10/26/2021","primary_txt":" Primary completion: 06/01/2025","primary_completion_date":" 06/01/2025","study_txt":" Completion: 12/01/2026","study_completion_date":" 12/01/2026","last_update_posted":"2024-06-11"},{"id":"91851c6c-8544-4437-8d34-90b527fa0625","acronym":"TUC-TOC","url":"https://clinicaltrials.gov/study/NCT05955170","created_at":"2023-07-21T16:11:20.614Z","updated_at":"2024-07-02T16:34:37.017Z","phase":"Phase 2","brief_title":"Tucatinib in Combination With Oral Etoposide andTrastuzumab in Patients With Metastatic HER2+ Breast Cancer","source_id_and_acronym":"NCT05955170 - TUC-TOC","lead_sponsor":"Institut Curie","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • capecitabine • Tukysa (tucatinib) • etoposide oral"],"overall_status":"Recruiting","enrollment":" Enrollment 66","initiation":"Initiation: 12/19/2023","start_date":" 12/19/2023","primary_txt":" Primary completion: 12/19/2026","primary_completion_date":" 12/19/2026","study_txt":" Completion: 12/19/2027","study_completion_date":" 12/19/2027","last_update_posted":"2024-06-07"},{"id":"8f620064-bf2c-4a41-a35d-eec67d66ae26","acronym":"MK-7119-002","url":"https://clinicaltrials.gov/study/NCT05382364","created_at":"2022-05-19T11:56:16.248Z","updated_at":"2024-07-02T16:35:00.872Z","phase":"Phase 1","brief_title":"Safety and Pharmacokinetics of Tucatinib (MK-7119) in Chinese Participants With Cancer (MK-7119-002)","source_id_and_acronym":"NCT05382364 - MK-7119-002","lead_sponsor":"Pfizer","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tukysa (tucatinib)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 25","initiation":"Initiation: 06/29/2022","start_date":" 06/29/2022","primary_txt":" Primary completion: 01/28/2025","primary_completion_date":" 01/28/2025","study_txt":" Completion: 12/29/2025","study_completion_date":" 12/29/2025","last_update_posted":"2024-05-27"},{"id":"c0f6572e-e0b9-41ba-be48-0dac251b1d1a","acronym":"A011801","url":"https://clinicaltrials.gov/study/NCT04457596","created_at":"2021-01-18T21:26:12.793Z","updated_at":"2024-07-02T16:35:01.275Z","phase":"Phase 3","brief_title":"T-DM1 and Tucatinib Compared With T-DM1 Alone in Preventing Relapses in People With High Risk HER2-Positive Breast Cancer, the CompassHER2 RD Trial","source_id_and_acronym":"NCT04457596 - A011801","lead_sponsor":"Alliance for Clinical Trials in Oncology","biomarkers":" ER • PGR","pipe":" | ","alterations":" HER-2 positive • ER positive • HR positive • HR negative • ER negative","tags":["ER • PGR"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • ER positive • HR positive • HR negative • ER negative"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e cisplatin • Kadcyla (ado-trastuzumab emtansine) • Tukysa (tucatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 1031","initiation":"Initiation: 01/06/2021","start_date":" 01/06/2021","primary_txt":" Primary completion: 01/01/2028","primary_completion_date":" 01/01/2028","study_txt":" Completion: 05/01/2035","study_completion_date":" 05/01/2035","last_update_posted":"2024-05-23"},{"id":"baab6d02-6aba-44b1-858f-b441267fa5e3","acronym":"TUTOR","url":"https://clinicaltrials.gov/study/NCT05553522","created_at":"2022-09-23T17:07:16.635Z","updated_at":"2024-07-02T16:35:05.681Z","phase":"Phase 1","brief_title":"Tucatinib, Trastuzumab, and Capecitabine With SRS for Brain Metastases From HER-2 Positive Breast Cancer","source_id_and_acronym":"NCT05553522 - TUTOR","lead_sponsor":"Baptist Health South Florida","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • capecitabine • Tukysa (tucatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 01/29/2024","start_date":" 01/29/2024","primary_txt":" Primary completion: 11/01/2024","primary_completion_date":" 11/01/2024","study_txt":" Completion: 11/01/2025","study_completion_date":" 11/01/2025","last_update_posted":"2024-05-06"},{"id":"c3f54891-da4a-41e1-8c9d-820b8590b4b8","acronym":"","url":"https://clinicaltrials.gov/study/NCT05892068","created_at":"2023-06-07T14:07:52.373Z","updated_at":"2024-07-02T16:35:06.832Z","phase":"Phase 2","brief_title":"A Study of Tucatinib Given Before Surgery to People With HER2+ Cancers That Have Spread to the Brain","source_id_and_acronym":"NCT05892068","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2","pipe":" | ","alterations":" HER-2 overexpression • HER-2 amplification","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 overexpression • HER-2 amplification"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Tukysa (tucatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 28","initiation":"Initiation: 05/09/2023","start_date":" 05/09/2023","primary_txt":" Primary completion: 05/09/2028","primary_completion_date":" 05/09/2028","study_txt":" Completion: 05/09/2028","study_completion_date":" 05/09/2028","last_update_posted":"2024-04-30"},{"id":"f2b35136-f790-410c-b54a-4f61af16101b","acronym":"ZWI-ZW25-101","url":"https://clinicaltrials.gov/study/NCT02892123","created_at":"2021-01-17T17:13:28.525Z","updated_at":"2024-07-02T16:35:08.789Z","phase":"Phase 1","brief_title":"Trial of ZW25 (Zanidatamab) in Patients With Advanced HER2-expressing Cancers","source_id_and_acronym":"NCT02892123 - ZWI-ZW25-101","lead_sponsor":"Jazz Pharmaceuticals","biomarkers":" EGFR • HER-2 • KRAS • ALK • ROS1","pipe":" | ","alterations":" HER-2 positive • HER-2 overexpression • EGFR wild-type • KRAS wild-type • ALK wild-type • RAS wild-type • EGFR wild-type + ALK wild-type • ALK-ROS1 fusion","tags":["EGFR • HER-2 • KRAS • ALK • ROS1"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 overexpression • EGFR wild-type • KRAS wild-type • ALK wild-type • RAS wild-type • EGFR wild-type + ALK wild-type • ALK-ROS1 fusion"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e paclitaxel • capecitabine • Tukysa (tucatinib) • vinorelbine tartrate • Ziihera (zanidatamab-hrii)"],"overall_status":"Active, not recruiting","enrollment":" Enrollment 279","initiation":"Initiation: 09/30/2016","start_date":" 09/30/2016","primary_txt":" Primary completion: 06/01/2024","primary_completion_date":" 06/01/2024","study_txt":" Completion: 07/01/2024","study_completion_date":" 07/01/2024","last_update_posted":"2024-04-18"},{"id":"4bf9de82-bc5d-4f41-96c1-1ff5dcf642d4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05672524","created_at":"2023-01-05T14:58:33.539Z","updated_at":"2024-07-02T16:35:09.423Z","phase":"Phase 2","brief_title":"A Study of Tucatinib and Trastuzumab in People With Rectal Cancer","source_id_and_acronym":"NCT05672524","lead_sponsor":"Memorial Sloan Kettering Cancer Center","biomarkers":" HER-2 • KRAS","pipe":" | ","alterations":" HER-2 positive • HER-2 overexpression • HER-2 amplification • RAS wild-type • KRAS exon 2 mutation • RAS wild-type + HER-2 positive • KRAS exon 3 mutation • KRAS exon 4 mutation","tags":["HER-2 • KRAS"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • HER-2 overexpression • HER-2 amplification • RAS wild-type • KRAS exon 2 mutation • RAS wild-type + HER-2 positive • KRAS exon 3 mutation • KRAS exon 4 mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Tukysa (tucatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 37","initiation":"Initiation: 12/30/2022","start_date":" 12/30/2022","primary_txt":" Primary completion: 12/30/2025","primary_completion_date":" 12/30/2025","study_txt":" Completion: 12/30/2025","study_completion_date":" 12/30/2025","last_update_posted":"2024-04-16"},{"id":"47f9cfd9-34f5-4833-94ff-741626e8ec0b","acronym":"","url":"https://clinicaltrials.gov/study/NCT01921335","created_at":"2021-01-17T17:24:48.029Z","updated_at":"2024-07-02T16:35:12.570Z","phase":"Phase 1","brief_title":"ARRY-380 + Trastuzuamab for Breast w/ Brain Mets","source_id_and_acronym":"NCT01921335","lead_sponsor":"Dana-Farber Cancer Institute","biomarkers":" HER-2","pipe":"","alterations":" ","tags":["HER-2"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Herceptin (trastuzumab) • Tukysa (tucatinib)"],"overall_status":"Completed","enrollment":" Enrollment 41","initiation":"Initiation: 08/01/2013","start_date":" 08/01/2013","primary_txt":" Primary completion: 03/01/2018","primary_completion_date":" 03/01/2018","study_txt":" Completion: 12/31/2023","study_completion_date":" 12/31/2023","last_update_posted":"2024-03-27"},{"id":"036cf4b7-1189-46bc-af75-d6b04605a8a4","acronym":"","url":"https://clinicaltrials.gov/study/NCT05230810","created_at":"2022-02-09T17:52:54.012Z","updated_at":"2025-02-25T15:54:21.438Z","phase":"Phase 1/2","brief_title":"Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.","source_id_and_acronym":"NCT05230810","lead_sponsor":"Criterium, Inc.","biomarkers":" EGFR • HER-2 • PIK3CA • CD4","pipe":" | ","alterations":" HER-2 positive • PIK3CA mutation","tags":["EGFR • HER-2 • PIK3CA • CD4"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e HER-2 positive • PIK3CA mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Piqray (alpelisib) • fulvestrant • Tukysa (tucatinib)"],"overall_status":"Recruiting","enrollment":" Enrollment 40","initiation":"Initiation: 08/25/2022","start_date":" 08/25/2022","primary_txt":" Primary completion: 08/30/2024","primary_completion_date":" 08/30/2024","study_txt":" Completion: 06/30/2025","study_completion_date":" 06/30/2025","last_update_posted":"2024-03-19"}]